Case report
Open access
Oct 2026
SGLT2 inhibitors and cardiovascular outcomes in patients with moderate-to-severe psoriasis receiving biologic therapy: A propensity score-matched cohort study.
SGLT2 inhibitor use was associated with favorable cardiovascular outcomes in patients with moderate-to-severe psoriasis receiving biologic therapy, and these findings support further prospective investigation of SGLT2 inhibitors as a potential strategy for cardiovascular risk reduction in this population.
A. Gotor-Rivera, J. Sánchez, E. C. Jiménez et al.
· Actas Dermo-Sifiliográficas · 0 citations